Does Wegovy burn fat, or does it only suppress appetite?

The biggest misconception: it's not a simple 'off switch' for hunger

Most people searching this question have heard Wegovy described as an appetite suppressant and nothing more, a drug that tricks you into eating less, with the weight loss following automatically from that. That picture is incomplete, and in some ways it undersells the medicine.

Semaglutide does slow gastric emptying quite markedly, so food sits in your stomach longer and fullness arrives sooner. It also acts on GLP-1 receptors in the hypothalamus, reducing the urgency of hunger and what many patients describe as constant background preoccupation with food. If you want to read more about that specific effect, how Wegovy affects appetite covers it in detail. But the mechanism doesn't stop at 'eat less, weigh less'. Semaglutide also appears to shift the body's preference toward using stored fat for energy, a distinct process from appetite regulation, even if the two are connected in practice.

The misconception matters because it shapes how people use the treatment. Someone who thinks Wegovy is purely an appetite drug may not understand why protein intake, resistance exercise, and consistent meal structure still matter alongside it. The medicine reduces the surplus calories coming in; what your body does with the deficit is partly determined by what else you put in place around the treatment.

What the evidence says about fat loss specifically

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks and found average weight reduction of around 15% at the 2.4mg maintenance dose. Body-composition analyses from the trial programme showed the majority of that weight came from fat mass rather than lean tissue, an important distinction, since medicines that cause disproportionate muscle loss can leave people metabolically worse off even at a lower number on the scale.

Semaglutide's role in fat metabolism appears to involve increased fat oxidation (the process by which stored fat is broken down for fuel) and some direct effects on fat-cell signalling. These are studied at a mechanistic level, though the clinical evidence is clearest on total weight loss and body composition rather than the precise biochemical pathways. The broader question of whether semaglutide produces real weight loss or only appetite changes is worth reading alongside this page, since the two questions are closely related.

In practical terms: the appetite reduction creates the calorie deficit; the metabolic shifts influence what your body draws on to fill that deficit. Both matter. Neither alone tells the whole story.

Why the distinction affects what you eat on treatment

If Wegovy only suppressed appetite, diet composition during treatment would be largely irrelevant, eat less of anything and the outcome would be the same. The evidence suggests otherwise. Because the body can draw on either fat or lean mass during a calorie deficit, the quality of what you eat (and whether you stay active) influences how that deficit is met. A diet low in protein, for instance, makes it harder for the body to preserve muscle tissue when overall intake falls sharply.

Our page on what to eat on Wegovy goes into the practical detail (protein targets, fibre, hydration) but the short version is that food choices still matter, even when the medicine is doing much of the work on portion sizes. Some people find this reassuring: the treatment is not doing everything for you, which means there are levers you control.

For those thinking about the wider picture of weight-loss treatment options, it's worth knowing that Wegovy's effects on fat metabolism are broadly similar to what research shows for semaglutide generally, the branded injection and the underlying molecule behave the same way. Whether that profile suits your situation is exactly the kind of question our prescribers work through with each patient. Our clinical team reviews every consultation personally, not by algorithm.

The honest answer to 'does it burn fat or just suppress appetite'

Both, with appetite suppression doing the heavier lifting. The calorie deficit produced by reduced hunger is the primary driver of fat loss on semaglutide; the direct metabolic effects on fat tissue are real but secondary. That combination is why the weight lost on Wegovy tends to be predominantly fat mass, and why the trial results (around 15% average loss over 68 weeks) look meaningfully different from simple calorie restriction alone, where muscle loss is often more pronounced.

There is a useful parallel question about whether Wegovy does more than suppress appetite (covering cardiovascular and liver-related research), and a separate one about how quickly the appetite effects appear for people who are newly starting treatment. For those curious whether the effect ever plateaus, whether appetite suppression is the only mechanism addresses that directly.

The NHS provides patient-level information on semaglutide, including how it works and its side-effect profile, on the NHS semaglutide medicines page. Wegovy is a Prescription-Only Medicine. No provider (including nume) can dispense it without a clinical assessment confirming it is appropriate for you as an individual. If you'd like that assessment, speak to our prescribers and we'll review your consultation the same day.